TARS Tarsus Pharmaceuticals Forecast, Technical & Fundamental Analysis
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care... Show more
TARS is expected to report earnings to rise 34.69% to -21 cents per share on August 06
Q2'26
Est.
$-0.22
Q1'26
Beat
by $0.14
Q4'25
Missed
by $0.12
Q3'25
Beat
by $0.05
Q2'25
Missed
by $0.10
The last earnings report on May 06 showed earnings per share of -15 cents, beating the estimate of -30 cents. With 678.87K shares outstanding, the current market capitalization sits at 2.74B.
A.I.dvisor indicates that over the last year, TARS has been loosely correlated with GMAB. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if TARS jumps, then GMAB could also see price increases.
TARS in +1.68% Uptrend, rising for three consecutive days on June 22, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where TARS advanced for three days, in of 280 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 09, 2026. You may want to consider a long position or call options on TARS as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for TARS just turned positive on June 08, 2026. Looking at past instances where TARS's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
TARS moved above its 50-day moving average on June 22, 2026 date and that indicates a change from a downward trend to an upward trend.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TARS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for TARS entered a downward trend on June 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.843) is normal, around the industry mean (20.966). P/E Ratio (0.000) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). TARS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (5.074) is also within normal values, averaging (367.026).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TARS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
